Lung Cancer ID (Identity) Study

Status Recruiting

Clinical Trial Summary

The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06076005
Study type	Observational
Source	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact	Rocco Trisolini, MD
Phone	0630154163
Email	rocco.trisolini@policlinicogemelli.it
Status	Recruiting
Phase
Start date	November 1, 2023
Completion date	October 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03668496` - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC	Phase 3
Active, not recruiting	`NCT03322072` - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating	N/A
Recruiting	`NCT05497973` - Psychosocial eHealth in Advanced Lung Cancer	N/A
Recruiting	`NCT05860296` - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers	Phase 1/Phase 2
Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
Completed	`NCT04825912` - Resilience Measurement in Older Adults With Late-Stage Lung Cancer	N/A
Completed	`NCT03529851` - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients	N/A
Completed	`NCT03558165` - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed	`NCT03076164` - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	Phase 1/Phase 2
Not yet recruiting	`NCT03153358` - Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation	Phase 2
Recruiting	`NCT04595734` - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting	`NCT04519983` - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs	Phase 2
Not yet recruiting	`NCT05701384` - Lazertinib 160mg in EGFR T790M NSCLC	Phase 2
Withdrawn	`NCT03409341` - Personalizing Immune Checkpoint Inhibitor Therapy
Active, not recruiting	`NCT03728361` - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer	Phase 2
Not yet recruiting	`NCT06024941` - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer	Phase 2
Recruiting	`NCT04669223` - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion	N/A
Recruiting	`NCT05996263` - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Completed	`NCT04057196` - Self-System Therapy for Older Adults With Lung Cancer	N/A
Recruiting	`NCT06000358` - The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer	N/A